Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program...
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during...
CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical trial of DB-OTO to patients...
AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
ALACHUA, Fla. and TAMPA, Fla., May 12, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval...
Total Revenue of $69.9 Million, an increase of 12.9% YoY Net Loss of $12.4 Million, an improvement of 37.0% YoY...
SAN FRANCISCO, May 12, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with...
CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
Elite Body Sculpture London 1 51 Harley Exterior Elite Body Sculpture London 2 51 Harley InteriorMIAMI BEACH, Fla., May 12,...
At the annual general meeting (the “AGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 12 May 2023...
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or...
Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on...
In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the...
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology...
Maylands, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- Maylands Dental Centre is a Dentist Perth that has recently launched free implant and...